The PRESERVED-HF trial assessed the primary end point of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS) and 6-minute walk test (6MWT) in 324 patients with HFpEF after 12 weeks of treatment with dapagliflozin.23 The study reported a 5.8-point improvement in KCCQ-CS and an improvement of 20.1 meters in the 6MWT, both statistically significant, while noticing reduced weight, but no differences were reported in the N-terminal pro–B-type natriuretic peptide (NT-proBNP), BNP levels, or other secondary end points. This evidence concerns the gene NPPB and hydrops fetalis.